Skip to main content
. 2015 Jan 21;6(8):5990–6000. doi: 10.18632/oncotarget.3337

Figure 6. YM155 is a promising therapeutic agent for patient-derived HCC xenograft expressing high survivin.

Figure 6

(A) The expression of survivin and p-survivin in three patient-derived HCC tissue samples were studied by Western blot analysis. (B) Weekly quantitative analysis of the tumour volume of all mice receiving different treatments as shown. (C) Endpoint image of the tumor of the P3 patient-derived HCC tissue samples following treatment with saline, sorafenib and YM155. (D) Expression of survivin in the tumor tissues studied by IHC analysis and the induction of apoptosis was studied by TUNEL staining (green cells = TUNEL+ cells).